The company
Vaxcyte, Inc.
PCVX · Nasdaq
Health CareBiotechnologyJust started moving
PCVX stood above a rising 150-day average in 41 of the last 52 weekly readings, including each of the last 3 weeks. It is 11.6% above that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Just started moving
- Weeks in an uptrend
- 3 in a row
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $21.0M
- Officials’ trades on record
- 10
- Institutions holding
- 310 (+0)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 41 of 52 weeks.
17 Apr – 16 Oct
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
1 Nov 2024 – 1 Oct 2026
Open-market buys above the line and sales below, in dollars.
Congress and officials
10 disclosed lines: House 9, Senate 0, executive 1; 4 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31 | bought | $1k–$15k | 16 Jul 2026filed 4 Sep 2026 |
| Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31 | bought | $1k–$15k | 13 May 2026filed 8 Jun 2026 |
| Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31 | bought | $1k–$15k | 12 May 2026filed 8 Jun 2026 |
| Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31 | bought | $1k–$15k | 28 Apr 2025filed 6 May 2025 |
| Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31 | bought | $1k–$15k | 15 Apr 2025filed 6 May 2025 |
| Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31 | bought | $1k–$15k | 14 Apr 2025filed 6 May 2025 |
| Jefferson Shreve House: U.S. House ClerkIN06 | sold | $15k–$50k | 5 Mar 2025filed 11 Apr 2025 |
| Sean P. Duffy Executive branch: Office of Government EthicsDepartment of Transportation | sold | $1k–$15k | 11 Feb 2025filed 14 May 2025 |
| Chris Jacobs House: U.S. House ClerkNY27 | sold | $1k–$15k | 12 Dec 2022filed 20 Jan 2023 |
| Chris Jacobs House: U.S. House ClerkNY27 | bought | $1k–$15k | 8 Nov 2022filed 12 Dec 2022 |
Insiders
Buy orders, 12 months0
Sale orders, 12 months24
Buyers · sellers0 · 5
| Who | Did | Shares | Traded |
|---|---|---|---|
| Jim WassilEVP, Chief Scientific Ofc, COO | sold | 18,000at $86.74 | 5 Oct 2026filed 7 Oct 2026 |
| Elvia CowanSVP, Finance & CAO | sold | 19,000at $86.74 | 5 Oct 2026filed 7 Oct 2026 |
| Jim WassilEVP, Chief Scientific Ofc, COO | sold | 2,155at $56.65 | 1 Oct 2026filed 2 Oct 2026 |
| Jim WassilEVP, Chief Scientific Ofc, COO | sold | 95at $57.09 | 1 Oct 2026filed 2 Oct 2026 |
| Jim WassilEVP, Chief Scientific Ofc, COO | sold | 1,334at $59.52 | 9 Sep 2026filed 9 Sep 2026 |
| Jim WassilEVP, Chief Scientific Ofc, COO | sold | 1,381at $61.16 | 4 Sep 2026filed 9 Sep 2026 |
| Jim WassilCHIEF OPERATING OFFICER | sold | 1,537at $60.89 | 1 Sep 2026filed 2 Sep 2026 |
| Jim WassilCHIEF OPERATING OFFICER | sold | 713at $61.48 | 1 Sep 2026filed 2 Sep 2026 |
| Jim WassilCHIEF OPERATING OFFICER | sold | 924at $60.96 | 1 Sep 2026filed 2 Sep 2026 |
| Jim WassilCHIEF OPERATING OFFICER | sold | 303at $61.42 | 1 Sep 2026filed 2 Sep 2026 |
| Harpreet S. DhaliwalChief Technical Ops Officer | sold | 17,000at $55.00 | 5 Aug 2026filed 5 Aug 2026 |
| Andrew GuggenhimePRESIDENT AND CFO | sold | 6,956at $53.76 | 3 Aug 2026filed 5 Aug 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Holders310+0 on the quarter
New · exited50 · 48
Reported value$8.9B
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| FMR LLCadded · filed 13 Aug 2026 | 20,852,907$1.2B | +4,360,046+26.4% |
| Jupiter Topco LLCnew · filed 14 Aug 2026 | 17,965,847$1.0B | +17,965,847 |
| BlackRock, Inc.added · filed 7 Aug 2026 | 12,068,129$701.5M | +1,096,313+10.0% |
| RA CAPITAL MANAGEMENT, L.P.unchanged · filed 14 Aug 2026 | 11,474,599$667.0M | 00.0% |
| WELLINGTON MANAGEMENT GROUP LLPadded · filed 14 Aug 2026 | 7,001,565$407.0M | +1,386,968+24.7% |
| VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 2026 | 6,593,551$383.3M | +314,006+5.0% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 6,348,679$369.0M | +81,978+1.3% |
| STATE STREET CORPadded · filed 7 Aug 2026 | 5,351,698$311.1M | +911,179+20.5% |
| Deep Track Capital, LPunchanged · filed 14 Aug 2026 | 4,300,000$250.0M | 00.0% |
| GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026 | 3,459,363$201.1M | +258,080+8.1% |
31 Mar 2023 – 30 Jun 2026
News
Show Me The Money: Vaxcyte Delivers 100%+ Gains As Pneumococcal Vaccine Program Advancesrttnews.com · 16 Oct 2026Vaxcyte Commences Proposed $500 Mln Equity & $500 Mln Notes Offering To Fund VAX-31 Programrttnews.com · 6 Oct 2026Vaxcyte Stock Hits New 52-Week High - Here's Whyaol.com · 5 Oct 2026Vaxcyte Shares Surge 39% On Positive Phase 3 VAX-31 Datarttnews.com · 5 Oct 2026Vaxcyte Set To Unveil Pivotal Phase 3 Data For Broad-Spectrum PCV Candidate; Today; Stock Uprttnews.com · 5 Oct 2026Broader Coverage And Strong Immune Responses Highlight Vaxcyte's Phase 3 Vaccine Readout; Stock Uprttnews.com · 5 Oct 2026Vaxcyte, Inc.: Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company's 31-Valent Pneumococcal Conjugate Vaccine Candidatefinanznachrichten.de · 5 Oct 2026Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filingyahoo.com · 8 Sep 2026
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.